Despite an overwhelming volume of publications suggesting that high levels of GREM1 contribute to cancer progression and worsening patient prognosis, the report from Lan and colleagues discussed above (Lan et al. 2022) and the apparent disparity around the oncogenic versus tumor suppressor role of GREM1 in pancreatic (and other) cancer must be carefully considered. This evidence concerns the gene GREM1 and cancer.